Rimegepant safety study for adults with migraine in India
Treatments studied
Part of Brain & nervous system clinical trials.
This study tests if the medicine rimegepant is safe for people with migraine. You may be able to join if you have had migraine for at least a year, have 4–14 migraine days per month, and have not had good results with other migraine medicines called triptans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had migraine for at least 1 year, with attacks lasting 4–72 hours if untreated.
- You currently have 4 to 14 migraine days per month and fewer than 7 non-migraine headache days.
- You have tried a triptan medicine and it either didn't work well, caused side effects, or you cannot take it for medical reasons.
- You do not have serious health problems like heart disease, uncontrolled high blood pressure, or certain psychiatric conditions.
- You are not currently taking certain migraine preventives or have not used them in a stable dose for at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking an additional dose of rimegepant (a migraine medicine you may already use) is safe and helpful for adults with migraine. Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist—a type of medicine that blocks a protein involved in migraine pain.
This Phase 3 study checks the long-term safety of rimegepant, a migraine treatment, in children and teens. You might join if your child has had migraine for at least 6 months and still gets a certain number of moderate-to-severe migraine attacks.
This study tests whether the medication rimegepant can help prevent chronic migraine in adults. It may be an option if you have frequent migraines and have not tried certain other preventive treatments.
This study tests if the drug rimegepant can help prevent migraine attacks in women. It aims to see how well it works in real life in China.
This study tests a medicine called rimegepant to see if it helps prevent migraines. If you have migraine at least 4 days per month, this might be for you.
This trial studies whether rimegepant can reduce how often migraine attacks happen in children and teens. It also looks at safety and how well the treatment fits day-to-day life and school activities.
Hear when a new Acute Treatment of Migraine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.